Modulation of Urokinase-type Plasminogen Activator Gene Expression by Inflammatory Cytokines in Human pre-B Lymphoma Cell Line RC-K8

Summary

We examined the effects of inflammatory cytokines, such as interleukin-lα (IL-lα), interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNFα), transforming growth factor-β (TGFβ) and lipopolysaccharide (LPS), on the urokinase-type plasminogen activator (uPA) gene expression in RC-K8 human pre-B lymphoma cells. Recombinant IL-1α, recombinant IL-1β and LPS but not recombinant IL-6, recombinant TNFα and TGFβ dose-dependently increased uPA accumulation in the conditioned medium. Northern blot analysis revealed that uPA mRNA levels rapidly increased with a peak induction at 2 h after stimulation with IL-lα and IL-1β, but uPA mRNA increase by LPS began at 9 h after stimulation and the increase was maintained until the experiment ended at 24 h. These responses were independent of de novo synthesis, rather amplified in the presence of a protein synthesis inhibitor. The effects by IL-1α and IL-1β were prevented by addition of anti-IL-1α and anti-IL-1β neutralizing antibodies, respectively. In contrast, both antibodies did not prevent LPS-induced uPA gene expression. Therefore, it is unlikely that the effect by LPS is through induction of IL-1. Both IL-1α and IL-1 β rapidly activated uPA gene transcription, but not increased stability of uPA mRNA. These results suggest that both IL-1α and IL-1 β cause a rapid activation of uPA gene transcription in which de novo protein synthesis is not required and that LPS induces uPA gene expression independently of the IL-1 pathway. These modulations of uPA production by inflammatory mediators may be implicated in tumor growth and metastasis.

• References

• 1 Wun TC, Schleuning WD, Reich E. Isolation and characterization of urokinase from human plasma. J Biol Chem 1982; 257: 3276-3283
• 2 Quax PH, van den Hoogen CM, Verheijen JH, Padro T, Zeheb R, Gelehrter TD, van Berkel TJ, Kuiper J, Emeis JJ. Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo. J Biol Chem 1990; 265: 15560-15563
• 3 Niedbala MJ, Stein M. Tumor necrosis factor induction of urokinase-type plasminogen activator in human endothelial cells. Biomed Biochim Acta 1991; 50: 427-436
• 4 Marshall BC, Xu QP, Rao NV, Brown BR, Hoidal JR. Pulmonary epithelial cell urokinase-type plasminogen activator. Induction by interleukin-1 beta and tumor necrosis factor-alpha J Biol Chem 1992; 267: 11462-11469
• 5 Gyetko MR, Wilkinson CC, Sitrin RG. Monocyte urokinase expression: modulation by interleukins. J Leukocyte Biol 1993; 53: 598-601
• 6 Busso N, Nicodeme E, Chesne C, Guillouzo A, Belin D, Hyafil F. Urokinase and type 1 plasminogen activator inhibitor production by normal human hepatocytes: modulation by inflammatory agents. Hepatology 1994; 20: 186-190
• 7 Wojta J, Zoellner H, Gallicchio M, Filonzi EL, Hamilton JA, McGrath K. Interferon-alpha 2 counteracts interleukin-1 alpha-stimulated expression of urokinase-type plasminogen activator in human foreskin mierovaseular endothelial cells in vitro. Lymphokine Cytokine Res 1994; 13: 133-138
• 8 Fenton MJ, Clark HD, Collins KL, Webb AC, Rich A, Auron PE. Transcriptional regulation of the human prointerleukin 1 beta gene. J Immunol 1987; 138: 3972-3979
• 9 de Bruin PA, Griffioen G, Verspaget HW, Verheijen JH, Lamers CB. Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas. Cancer Res 1987; 47: 4654-4657
• 10 Boyd D, Florent G, Kim P, Brattain M. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res 1988; 48: 3112-3116
• 11 Duffy MJ, O’Grady P, Devaney D, O’Siorain L, Fennelly JJ, Lijnen HJ. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report Cancer 1988; 62: 531-533
• 12 Nagamine Y, Reich TE. Gene expression and cAMP. Proc Natl Acad Sci USA 1985; 82: 4606-4610
• 13 Jans DA, Resink TJ, Hemmings BA. Dependence of urokinase-type-plasminogen-activator induction on cyclic AMP-dependent protein kinase activation in LLC-PKI cells. Biochem J 1987; 243: 413-418
• 14 Belin D, Godeau F, Vassalli JD. Tumor promoter PMA stimulates the synthesis and secretion of mouse pro-urokinase in MSV-transformed 3T3 cells: this is mediated by an increase in urokinase mRNA content. EMBO J 1984; 3: 1901-1906
• 15 Ferraiuolo R, Stoppelli MP, Verde P, Bullock S, Lazzaro P, Blasi F, Pietro-paolo TC. Transcriptional induction of urokinase in cultured human kidney carcinoma cells by tetradecanoyl-phorbol-acetate. J Cell Physiol 1984; 121: 368-374
• 16 Degen JL, Estensen RD, Nagamine Y, Reich E. Induction and desensitization of plasminogen activator gene expression by tumor promoters. J Biol Chem 1985; 260: 12426-12433
• 17 Stoppelli MP, Verde P, Grimaldi G, Locatelli EK, Blasi F. Increase in urokinase plasminogen activator mRNA synthesis in human carcinoma cells is a primary effect of the potent tumor promoter, phorbol myristate acetate. J Cell Biol 1986; 102: 1235-1241
• 18 Shinbo M, Niiya K, Al-mokdad M, Hayakawa Y, Hiraga K, Fujimaki M, Sakuragawa N. Protein kinase activity-dependent inhibition of urokinase- type plasminogen activator gene transcription by cyclic AMP in human pre-B lymphoma cell line RC-K8. Biochim Biophys Acta 1995; 1268: 293-299
• 19 Kubonishi I, Niiya K, Miyoshi I. Establishment of a new human lymphoma line that secretes plasminogen activator. Jpn J Cancer Res 1985; 76: 12-15
• 20 Kubonishi I, Niiya K, Yamashita M, Yano S, Abe T, Ohtsuki Y, Miyoshi I. Characterization of a new human lymphoma cell line (RC-K8) with t(11; 14) chromosome abnormality. Cancer 1986; 58: 1453-1460
• 21 Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Dano K, Appella E, Blasi F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis [published erratum appears in EMBO J 1990 May; 9 (5): 1674]. EMBO J 1990; 9: 467-474
• 22 Ellis V, Pyke C, Eriksen J, Solberg H, Dano K. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. [Review]. Ann NY Acad Sci 1992; 667: 13-31
• 23 Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 1993; 90: 5021-5025
• 24 Niiya K, Nsimba M, Hayashi T, Sakuragawa N. Down-regulation of urokinase secretion from a human lymphoma cell line RC-K8 by dexamethasone without inducing plasminogen activator inhibitors. Thromb Res 1992; 65: 311-321
• 25 Sambrook J, Fritsh EF, Maniatis T. Molecular Cloning. A Laboratory Manual 2 Cold Spring Harbor Laboratory 1989 p 7-39
• 26 Niiya K, Taniguchi T, Shinbo M, Ishikawa T, Tazawa S, Hayakawa Y, Sakuragawa N. Different regulation of plasminogen activator inhibitor 2 gene expression by phorbol ester and cAMP in human myeloid leukemia cell line PL-21. Thromb Haemost 1994; 72: 92-7
• 27 Greenberg ME, Ziff EB. Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogen. Nature 1984; 311: 433-438
• 28 Haeffner-Cavaillon N, Cavaillon JM, Moreau M, Szabo L. Interleukin 1 secretion by human monocytes stimulated by the isolated polysaccharide region of the Bordetella pertussis endotoxin. Mol Immunol 1984; 21: 389-395
• 29 Cavaillon JM, Haeffner-Cavaillon N. The role of serum in interleukin I production by human monocytes activated by endotoxins and their polysaccharide moieties. Immunol Lett 1985; 10: 35-41
• 30 Gaylis FD, Keer HN, Wilson MJ, Kwaan HC, Sinha AA, Kozlowski JM. Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. J Urol 1989; 142: 193-198
• 31 Cohen RL, Xi XP, Crowley CW, Lucas BK, Levinson AD, Shuman MA. Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells. Blood 1991; 78: 479-487
• 32 Ossowski L. Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase. Cancer Res 1992; 52: 6754-6760
• 33 Sims JE, Gayle MA, Slack JL, Alderson MR, Bird TA, Giri JG, Colotta F, Re F, Mantovani A, Shanebeck K, Grabstein KH, Dower SK. Interleukin 1 signaling occurs exclusively via the type I receptor. Proc Natl Acad Sci USA 1993; 90: 6155-6159
• 34 Leung K, Betts JC, Xu L, Nabel GJ. The cytoplasmic domain of the interleukin-1 receptor is required for nuclear factor-kappa B signal transduction. J Biol Chem 1994; 269: 1579-1582
• 35 Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986; 46: 705-716
• 36 Novak U, Cocks BG, Hamilton JA. A labile repressor acts through the NFkB-like binding sites of the human urokinase gene. Nucleic Acids Res 1991; 19: 3389-3393
• 37 Geng Y, Gulbins E, Altman A, Lotz M. Monocyte deactivation by interleukin 10 via inhibition of tyrosine kinase activity and the Ras signaling pathway. Proc Natl Acad Sci USA 1994; 91: 8602-8606
• 38 Tsukada J, Saito K, Waterman WR, Webb AC, Auron PE. Transcription factors NF-IL6 and CREB recognize a common essential site in the human prointerleukin 1 beta gene. Mol Cell Biol 1994; 14: 7285-7297
• 39 Godambe SA, Chaplin DD, Takova T, Bellone CJ. Upstream NFIL-6-like site located within a DNase I hypersensitivity region mediates LPS-induced transcription of the murine interleukin-1 beta gene. J Immunol 1994; 153: 143-152
• 40 Reimann T, Buscher D, Hipskind RA, Krautwald S, Lohmann-Matthes ML, Baccarini M. Lipopolysaccharide induces activation of the Raf-l/MAP kinase pathway. A putative role for Raf-1 in the induction of the IL-1 beta and the TNF-alpha genes. J Immunol 1994; 153: 5740-5749